Key result
ATRIO-CKM study protocol evaluates atrial cardiomyopathy prevalence across stages of cardiovascular-kidney-metabolic syndrome.
Why the study?
The distribution of atrial cardiomyopathy across cardiovascular-kidney-metabolic syndrome stages has not been characterized in routine clinical practice.
Cross-Sectional (n=200)
No
This study protocol aims to characterize the stage-specific prevalence and non-invasive profile of atrial cardiomyopathy across cardiovascular-kidney-metabolic syndrome stages to support earlier detection before overt arrhythmias or heart failure manifest.
Answers are grounded in this paper and cite their sources.
May guide non-invasive atrial cardiomyopathy phenotyping in CKM patients; leaves open stage-specific prevalence until results accrue.
Background/Objectives: In cardiovascular-kidney-metabolic (CKM) syndrome, left atrium (LA) involvement begins early: reservoir function declines before the chamber dilates, and the resulting atrial cardiomyopathy (ACM) precedes atrial fibrillation (AF), heart failure with preserved ejection fraction (HFpEF), and cardioembolic stroke. How ACM is distributed across CKM stages has not yet been characterized in routine clinical practice. ATRIO-CKM aims to characterize ACM non-invasively across the range of CKM stages in patients assessed in an internal medicine and cardiology department and to identify the parameters most strongly associated with ACM within CKM syndrome. Methods: Single-center, prospective, observational study with cross-sectional phenotyping at the index visit. We will enroll consecutive adults at their first assessment in our department (target, 200; minimum, 150). The primary objective is to estimate the stage-specific prevalence of ACM among participants in sinus rhythm without documented AF, who form the main cohort and are grouped as CKM with versus without ACM. Patients in sinus rhythm are phenotyped with 12-lead electrocardiogram (P-wave duration, Bayés interatrial block), echocardiography with speckle-tracking of the left ventricle (LV), LA (biplane reservoir, conduit, and contractile strain), and right ventricular (RV) free wall, and biomarkers including MR-proANP, Fetuin-A, FGF-23, and NT-proBNP, with cardiac magnetic resonance in an exploratory subset. Participants with AF documented at any time, including previously documented paroxysmal AF, are allocated to a separate established-AF cohort irrespective of the rhythm at the index visit. Results: We will report ACM prevalence by CKM stage with confidence intervals, the profile separating the two groups, LA volume index across three groups of increasing severity (no ACM, ACM in sinus rhythm, and established AF), and the parameters associated with ACM. Conclusions: Using only measurements already available in routine cardiology, ATRIO-CKM will describe how ACM is distributed across CKM stages and identify the parameters most strongly associated with ACM within CKM syndrome, as candidates for a classification index to be developed and validated in a larger cohort.
No takes yet. Share an insight, caveat, or question.
Godun et al. (2026) conducted a cross-sectional in Cardiovascular-Kidney-Metabolic (CKM) Syndrome and Atrial Cardiomyopathy (n=200). Cardiovascular-kidney-metabolic (CKM) syndrome stage vs. Lower CKM stages or CKM without ACM was evaluated on Stage-specific prevalence of atrial cardiomyopathy (ACM) among participants in sinus rhythm without documented atrial fibrillation. The ATRIO-CKM study is a cross-sectional protocol to evaluate the prevalence of atrial cardiomyopathy across cardiovascular-kidney-metabolic syndrome stages, with results pending.
Synapse has enriched 10 related papers. Consider them for comparative context: